{
    "id": "33fbf0f4-50c6-80c0-e063-6394a90a221d",
    "indications": "decitabine injection indicated treatment adult patients myelodysplastic syndromes ( mds ) including previously treated untreated , de novo secondary mds french-american-british subtypes ( refractory anemia , refractory anemia ringed sideroblasts , refractory anemia excess blasts , refractory anemia excess blasts transformation , chronic myelomonocytic leukemia ) intermediate-1 , intermediate-2 , high-risk international prognostic scoring system groups .",
    "contraindications": "• three day regimen : administer decitabine injection dose 15 mg/m 2 continuous intravenous infusion 3 hours repeated every 8 hours 3 days . repeat cycle every 6 weeks . ( 2.1 ) • five day regimen : administer decitabine injection dose 20 mg/m 2 continuous intravenous infusion 1 hour repeated daily 5 days . repeat cycle every 4 weeks . ( 2.1 )",
    "warningsAndPrecautions": "decitabine injection sterile , white almost white lyophilized powder intravenous supplied : ndc 68001-642-41 , 50 mg single-dose vial individually packaged carton . store vials 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "MONOBASIC POTASSIUM PHOSPHATE",
            "code": "4J9FJ0HL51"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "DECITABINE",
            "code": "776B62CQ27"
        }
    ],
    "organization": "BluePoint Laboratories",
    "name": "Decitabine",
    "effectiveTime": "20250501",
    "indications_original": "Decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",
    "contraindications_original": "• Three Day Regimen : Administer decitabine for injection at a dose of 15 mg/m 2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. Repeat cycle every 6 weeks. (2.1) • Five Day Regimen : Administer decitabine for injection at a dose of 20 mg/m 2 by continuous intravenous infusion over 1 hour repeated daily for 5 days. Repeat cycle every 4 weeks. (2.1)",
    "warningsAndPrecautions_original": "Decitabine for injection is a sterile, white to almost white lyophilized powder for intravenous use supplied as:\n                  \n                  \n                  \n                  NDC 68001-642-41, 50 mg single-dose vial individually packaged in a carton.\n                  \n                  \n                  \n                  Store vials at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "None."
}